Ocular Drug Delivery System Market Forecast, Trend Analysis & Opportunity Assessment 2021-2031
A recent market study published by Future Market Insights (FMI) on the market offers a global industry analysis for 2016-2020 & an opportunity assessment for 2021-2031. The report consists of a comprehensive assessment of the most important market dynamics.
On conducting thorough research on the historical as well as current growth parameters of the ocular drug delivery systems market, growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the ocular drug delivery systems market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the ocular drug delivery systems market in the coming years.
The report provides detailed information about the current and future growth prospects of the ocular drug delivery systems market in the most comprehensive way for better understanding of readers.
Key Segments of Ocular drug delivery systems Market
FMI’s study on the ocular drug delivery systems market offers information divided into four important segments— technology, dosage form, distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Technology
Implantable Ocular Drug Delivery Systems
Particulate Drug Delivery Systems
Nano-Particle Drug Delivery System
Dosage Form
Ophthalmic Solution
Ophthalmic Suspension
Ophthalmic Emulsion
Ophthalmic Gels
Ophthalmic Ointments
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Store
Mail Order Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Report Chapters:
Chapter 1 – Executive Summary
The report commences with the executive summary of the ocular drug delivery systems market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the ocular drug delivery systems market as well as the key trends impacting the market.
Chapter 2 – Market Overview
Readers can find detailed taxonomy and product definitions of the ocular drug delivery systems market, in this chapter, which help readers understand basic information about ocular drug delivery systems.
Chapter 3 – Key Market Trends
This section highlights the key trends impacting the ocular drug delivery systems market, which will help readers understand the current trends and their impact on market growth.
Chapter 4 – Market Background
This section tells us about micro and macro-economic factors that affect the market. And the drivers, restrain and future opportunities in this market and the growth of market in ocular drug delivery systems sector. In addition, the global GDP and health care expenditure affect the market.
Chapter 5 – Market Context
This chapter explains new API drug launches and regulatory approvals, key promotional strategies, and regulatory scenarios which can act as key success factors for the ocular drug delivery systems market during the forecast period.
Chapter 6 – Covid-19 Crisis Impact Analysis
This section tells us about the impact of covid-19 on ocular drug delivery systems market in base year and forecast years.
Chapter 7 – Global Ocular Drug Delivery Systems Market Demand (in Volume Units) Analysis 2016-2020 and Forecast, 2021-2031
This section explains the global market volume analysis and forecast for the ocular drug delivery systems during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2021–2031).
Chapter 8 – Global Ocular Drug Delivery Systems Market - Pricing Analysis
This section explains the global market pricing analysis and forecast for the ocular drug delivery systems during the forecast period.
Chapter 9 – Ocular Drug Delivery Systems Market Demand (Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
This section explains the global market value analysis and forecast for the ocular drug delivery systems during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2021–2031).
Chapter 10 – Global Ocular Drug Delivery Systems Market Analysis (2016-2020) & Opportunity Assessment (2021-2031), By Technology
Based on technology, the ocular drug delivery systems market is segmented into key products commercially available, (implantable ocular drug delivery systems, particulate drug delivery systems, nano-particle drug delivery system) In this chapter, readers can find information about a detailed analysis of the market by different treatment of ocular drug delivery systems and their growth over the forecast period.
Chapter 11 – Global Ocular Drug Delivery Systems Market Analysis 2016-2020 & Opportunity Assessment, 2021-2031, By Dosage Form
Based on dosage form, the ocular drug delivery systems market is segmented into ophthalmic solution, ophthalmic suspension, ophthalmic emulsion, ophthalmic gels, and ophthalmic ointments. In this chapter, readers can find information on market attractive analysis based on key target features of the product.
Chapter 12 – Global Ocular Drug Delivery Systems Market Analysis 2016-2020 & Opportunity Assessment, 2021-2031, By Distribution Channel
Based on distribution channel, the ocular drug delivery systems market is segmented into hospital pharmacy, retail pharmacy, drug store, mail order pharmacy. In this chapter, readers can find information on market attractive analysis based on key materials.
Chapter 13 – Global Ocular Drug Delivery System Market Analysis 2016-2020 & Opportunity Assessment 2021-2031, By Region
This chapter explains how the ocular drug delivery system market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA).
Chapter 14 – North Ocular Drug Delivery System Devices Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter includes a detailed analysis of the growth of the North America ocular drug delivery systems market along with the country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on technology, dosage form, distribution channel and region.
Chapter 15 – Latin America Ocular Drug Delivery Systems Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter includes the growth prospects of the ocular drug delivery systems market in leading countries such as Brazil, Mexico, and the rest of Latin America. Readers can find thorough information about the growth parameters of the Latin America ocular drug delivery systems market during 2021-2031.
Chapter 16 – Europe Ocular drug delivery systems Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
Important growth prospects of the ocular drug delivery systems market based on technology, dosage form, distribution channel and region and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, BENELUX, and Rest of Europe are included in this chapter.
Chapter 17 – South Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
India, Indonesia, Malaysia, Thailand, and the rest of South Asia are the leading countries/regions in South Asia that are the prime subjects of assessment to obtain the growth prospects of the South Asia ocular drug delivery systems market, in this chapter, readers can find thorough information about the growth parameters of the South Asia ocular drug delivery systems market during 2030.
Chapter 18 – East Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
Detailed information about factors such as incremental opportunity, Y-O-Y growth, and regional trends that are impacting the growth of the East Asia ocular drug delivery systems market are included in this chapter. It also includes the growth prospects of the ocular drug delivery systems market in leading East Asian countries such as China, Japan, and South Korea.
Chapter 19 – Oceania Ocular Drug Delivery Systems Market Analysis 2016–2020 and Forecast 2020–2030
This chapter consists of important parameters that have a huge impact on the growth of the ocular drug delivery systems market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania ocular drug delivery systems market.
Chapter 20 – MEA Ocular Drug Delivery Systems Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter provides information on how the ocular drug delivery systems market will grow in the major countries in MEA region, such as GCC Countries, South Africa, Northern Africa and Rest of MEA during 2021-2031.
Chapter 21 – Key and Emerging Countries Ocular Drug Delivery Systems Market Analysis 2016-2020 & Opportunity Assessment 2021-2031
This chapter provides information on how the ocular drug delivery systems market will grow in the major countries across the world during 2021-2031.
Chapter 22 – Market Structure Analysis
This chapter covers the market analysis of competitors based on revenue tiers, single point view of portfolio across industry segments, and their relative market position.
Chapter 23 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the leading stakeholders in the ocular drug delivery systems market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments.
Players featured in the ocular drug delivery systems market report Allergan Plc., Graybug Vision Inc., Ocular Therapeutix, Inc., Alimera Sciences, pSivida, Santen Pharmaceutical Co., Ltd, Taiwan Liposome Company Ltd., Envisia Therapeutics, Eyegate Pharma, Valeant Pharmaceuticals International, Inc, Vision Ophthalmology Group GmbH, Clearside Biomedical, URSAPHARM Arzneimittel GmbH.
Chapter 24 – Assumptions and Acronyms Used
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.
Chapter 25 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the ocular drug delivery systems market.
Sources and Primary Research Splits (%)
Industry Interactions
Key Designations
C - Level Executives
Marketing Directors
Product Managers
Business Development Officers
Production Managers
Procurement Heads
Sales Executives
Stakeholder Category
Distributors
Traders
Raw Material Suppliers
Industry Experts
Consumptions
Questions
Current Market Dynamics and Challenges
Yesteryear Trends
Market Characteristics
Market Performance and Growth Quadrants
Competition Structure and Market Structure
Strategic Growth Initiatives
Near-term and Long-term Market Growth Prospects
Market Segment Splits and Authenticity
Opinions on Market Projections and Validity of Assumptions
References Catalogue
Industry Publications
World Health Organizations (WHO)
National Institute of Health (NIH)
Factiva
Company Press Releases
Annual Reports and Investor Presentations
Research Papers
Government Websites and Publications
Company Websites,
Morningstar
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusion & Exclusion
- 3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
- 4. Market Background
- 4.1. Macro-Economic Factors
- 4.1.1. GDP Growth Outlook
- 4.1.2. Global Healthcare Industry Outlook
- 4.1.3. Increasing Per Capita Healthcare Spending
- 4.1.4. Income Per Capita Outlook
- 4.2. Forecast Factors - Relevance & Impact
- 4.2.1. Product Availability
- 4.2.2. Rising Demand of Non-Invasive Ocular Drug Delivery Techniques
- 4.2.3. Global Ocular Drug Delivery Systems Market Statistics
- 4.2.4. Increase in Technological Advancement
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunity Analysis
- 5. Market Context
- 5.1. Key Product Features and Their USPs
- 5.2. Product Adoption / Usage Analysis
- 5.3. Key Promotional Strategies, By Manufacturers
- 5.4. Regulations, By Region
- 5.5. Reimbursement Scenario
- 6. COVID19 Crisis Analysis
- 6.1. Current Economic Projection as compared to 2008 financial analysis
- 6.2. COVID19 and Impact Analysis
- 6.2.1. Revenue by Product
- 6.2.2. Revenue by Dosage Form
- 6.2.3. Revenue by Distribution Channel
- 6.2.4. Revenue by Country
- 6.3. 2020 Market Scenario
- 7. Global Ocular Drug Delivery Systems Market Volume (Units) Analysis 2016-2020 and Forecast, 2021-2031
- 7.1. Historical Market Volume (Units) Analysis, 2016-2020
- 7.2. Current and Future Market Volume (Units) Projections, 2021-2031
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
- 8. Global Ocular Drug Delivery Systems Market - Pricing Analysis
- 8.1. Country Pricing Analysis by Technology
- 8.2. Pricing Break-up
- 8.2.1. Manufacturer Level Pricing
- 8.2.2. Distributor Level Pricing
- 8.3. Latin America and Middle East Average Pricing Analysis Benchmark
- 9. Global Ocular Drug Delivery Systems Market Value Analysis 2016-2020 and Forecast, 2021-2031
- 9.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
- 9.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
- 9.2.1. Y-o-Y Growth Trend Analysis
- 9.2.2. Absolute $ Opportunity Analysis
- 10. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Technology
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis by Technology, 2016-2020
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Technology, 2021-2031
- 10.3.1. Implantable Ocular Drug Delivery Systems
- 10.3.2. Particulate Drug Delivery Systems
- 10.3.3. Nano-Particle drug Delivery systems
- 10.4. Market Attractiveness Analysis by Technology
- 11. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Dosage Form
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) Analysis by Dosage Form, 2016-2020
- 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Dosage Form, 2021-2031
- 11.3.1. Ophthalmic Solution
- 11.3.2. Ophthalmic Suspension
- 11.3.3. Ophthalmic Emulsion
- 11.3.4. Ophthalmic Gels
- 11.3.5. Ophthalmic Ointments
- 11.4. Market Attractiveness Analysis by Dosage Form
- 12. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
- 12.1. Introduction / Key Findings
- 12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020
- 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
- 12.3.1. Hospital Pharmacies
- 12.3.2. Retail Pharmacies
- 12.3.3. Drug Stores
- 12.3.4. Mail Order Pharmacies
- 12.4. Market Attractiveness Analysis by Distribution Channel
- 13. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Region
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
- 13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
- 13.3.1. North America
- 13.3.2. Latin America
- 13.3.3. Europe
- 13.3.4. East Asia
- 13.3.5. South Asia
- 13.3.6. Oceania
- 13.3.7. Middle East and Africa (MEA)
- 13.4. Market Attractiveness Analysis By Region
- 14. North America Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 14.3.1. By Country
- 14.3.1.1. U.S.
- 14.3.1.2. Canada
- 14.3.2. By Technology
- 14.3.3. By Dosage Form
- 14.3.4. By Distribution Channel
- 14.4. Market Attractiveness Analysis
- 14.5. Key Market Participants - Intensity Mapping
- 14.6. Drivers and Restraints - Impact Analysis
- 15. Latin America Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 15.3.1. By Country
- 15.3.1.1. Brazil
- 15.3.1.2. Mexico
- 15.3.1.3. Argentina
- 15.3.1.4. Rest of Latin America
- 15.3.2. By Technology
- 15.3.3. By Dosage Form
- 15.3.4. By Distribution Channel
- 15.4. Market Attractiveness Analysis
- 15.5. Key Market Participants - Intensity Mapping
- 15.6. Drivers and Restraints - Impact Analysis
- 16. Europe Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 16.3.1. By Country
- 16.3.1.1. Germany
- 16.3.1.2. Italy
- 16.3.1.3. France
- 16.3.1.4. U.K.
- 16.3.1.5. Spain
- 16.3.1.6. Russia
- 16.3.1.7. Rest of Europe
- 16.3.2. By Technology
- 16.3.3. By Dosage Form
- 16.3.4. By Distribution Channel
- 16.4. Market Attractiveness Analysis
- 16.5. Key Market Participants - Intensity Mapping
- 16.6. Drivers and Restraints - Impact Analysis
- 17. South Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 17.3.1. By Country
- 17.3.1.1. India
- 17.3.1.2. Thailand
- 17.3.1.3. Indonesia
- 17.3.1.4. Malaysia
- 17.3.1.5. Rest of South Asia
- 17.3.2. By Technology
- 17.3.3. By Dosage Form
- 17.3.4. By Distribution Channel
- 17.4. Market Attractiveness Analysis
- 17.5. Key Market Participants - Intensity Mapping
- 17.6. Drivers and Restraints - Impact Analysis
- 18. East Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 18.3.1. By Country
- 18.3.1.1. China
- 18.3.1.2. Japan
- 18.3.1.3. South Korea
- 18.3.1.4. Rest of East Asia
- 18.3.2. By Technology
- 18.3.3. By Dosage Form
- 18.3.4. By Distribution Channel
- 18.4. Market Attractiveness Analysis
- 18.5. Key Market Participants - Intensity Mapping
- 18.6. Drivers and Restraints - Impact Analysis
- 19. Oceania Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 19.1. Introduction
- 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 19.3.1. By Country
- 19.3.1.1. Australia
- 19.3.1.2. New Zealand
- 19.3.2. By Technology
- 19.3.3. By Dosage Form
- 19.3.4. By Distribution Channel
- 19.4. Market Attractiveness Analysis
- 19.5. Key Market Participants - Intensity Mapping
- 19.6. Drivers and Restraints - Impact Analysis
- 20. Middle East and Africa Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 20.1. Introduction
- 20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
- 20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
- 20.3.1. By Country
- 20.3.1.1. GCC Countries
- 20.3.1.2. South Africa
- 20.3.1.3. Rest of Middle East and Africa
- 20.3.2. By Technology
- 20.3.3. By Dosage Form
- 20.3.4. By Distribution Channel
- 20.4. Market Attractiveness Analysis
- 20.5. Key Market Participants - Intensity Mapping
- 20.6. Drivers and Restraints - Impact Analysis
- 21. Key and Emerging Countries Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031
- 21.1. Introduction
- 21.1.1. Market Value Proportion Analysis, By Key Countries
- 21.1.2. Global Vs. Country Growth Comparison
- 21.2. U.S. Ocular Drug Delivery Systems Market Analysis
- 21.2.1. By Technology
- 21.2.2. By Dosage Form
- 21.2.3. By Distribution Channel
- 21.3. Canada Ocular Drug Delivery Systems Market Analysis
- 21.3.1. By Technology
- 21.3.2. By Dosage Form
- 21.3.3. By Distribution Channel
- 21.4. Mexico Ocular Drug Delivery Systems Market Analysis
- 21.4.1. By Technology
- 21.4.2. By Dosage Form
- 21.4.3. By Distribution Channel
- 21.5. Brazil Ocular Drug Delivery Systems Market Analysis
- 21.5.1. By Technology
- 21.5.2. By Dosage Form
- 21.5.3. By Distribution Channel
- 21.6. U.K. Ocular Drug Delivery Systems Market Analysis
- 21.6.1. By Technology
- 21.6.2. By Dosage Form
- 21.6.3. By Distribution Channel
- 21.7. Germany Ocular Drug Delivery Systems Market Analysis
- 21.7.1. By Technology
- 21.7.2. By Dosage Form
- 21.7.3. By Distribution Channel
- 21.8. France Ocular Drug Delivery Systems Market Analysis
- 21.8.1. By Technology
- 21.8.2. By Dosage Form
- 21.8.3. By Distribution Channel
- 21.9. Italy Ocular Drug Delivery Systems Market Analysis
- 21.9.1. By Technology
- 21.9.2. By Dosage Form
- 21.9.3. By Distribution Channel
- 21.10. Spain Ocular Drug Delivery Systems Market Analysis
- 21.10.1. By Technology
- 21.10.2. By Dosage Form
- 21.10.3. By Distribution Channel
- 21.11. BENELUX Ocular Drug Delivery Systems Market Analysis
- 21.11.1. By Technology
- 21.11.2. By Dosage Form
- 21.11.3. By Distribution Channel
- 21.12. Russia Ocular Drug Delivery Systems Market Analysis
- 21.12.1. By Technology
- 21.12.2. By Dosage Form
- 21.12.3. By Distribution Channel
- 21.13. China Ocular Drug Delivery Systems Market Analysis
- 21.13.1. By Technology
- 21.13.2. By Dosage Form
- 21.13.3. By Distribution Channel
- 21.14. Japan Ocular Drug Delivery Systems Market Analysis
- 21.14.1. By Technology
- 21.14.2. By Dosage Form
- 21.14.3. By Distribution Channel
- 21.15. South Korea Ocular Drug Delivery Systems Market Analysis
- 21.15.1. By Technology
- 21.15.2. By Dosage Form
- 21.15.3. By Distribution Channel
- 21.16. India Ocular Drug Delivery Systems Market Analysis
- 21.16.1. By Technology
- 21.16.2. By Dosage Form
- 21.16.3. By Distribution Channel
- 21.17. ASEAN Ocular Drug Delivery Systems Market Analysis
- 21.17.1. By Technology
- 21.17.2. By Dosage Form
- 21.17.3. By Distribution Channel
- 21.18. Australia Ocular Drug Delivery Systems Market Analysis
- 21.18.1. By Technology
- 21.18.2. By Dosage Form
- 21.18.3. By Distribution Channel
- 21.19. New Zealand Ocular Drug Delivery Systems Market Analysis
- 21.19.1. By Technology
- 21.19.2. By Dosage Form
- 21.19.3. By Distribution Channel
- 21.20. GCC Countries Ocular Drug Delivery Systems Market Analysis
- 21.20.1. By Technology
- 21.20.2. By Dosage Form
- 21.20.3. By Distribution Channel
- 21.21. Turkey Ocular Drug Delivery Systems Market Analysis
- 21.21.1. By Technology
- 21.21.2. By Dosage Form
- 21.21.3. By Distribution Channel
- 21.22. South Africa Ocular Drug Delivery Systems Market Analysis
- 21.22.1. By Technology
- 21.22.2. By Dosage Form
- 21.22.3. By Distribution Channel
- 22. Market Structure Analysis
- 22.1. Market Analysis by Tier of Companies
- 22.2. Market Concentration
- 22.3. Market Share Analysis of Top Players
- 22.4. Market Presence Analysis
- 22.4.1. By Regional Foot Print of Players
- 22.4.2. Product Foot Print by Players
- 22.4.3. Channel Foot Print by Players
- 23. Competition Analysis
- 23.1. Competition Dashboard
- 23.2. Competition Benchmarking
- 23.3. Competition Deep Dive
- 23.3.1. Allergan Plc.
- 23.3.1.1. Overview
- 23.3.1.2. Product Portfolio
- 23.3.1.3. Analyst Commentary
- 23.3.1.4. Key Financials
- 23.3.1.5. Recent Developments
- 23.3.1.6. Sales Footprint
- 23.3.1.7. Strategy Overview
- 23.3.1.7.1. Marketing Strategy
- 23.3.1.7.2. Product Strategy
- 23.3.1.7.3. Channel Strategy
- 23.3.2. Graybug Vision Inc.
- 23.3.2.1. Overview
- 23.3.2.2. Product Portfolio
- 23.3.2.3. Analyst Commentary
- 23.3.2.4. Key Financials
- 23.3.2.5. Recent Developments
- 23.3.2.6. Sales Footprint
- 23.3.2.7. Strategy Overview
- 23.3.2.7.1. Marketing Strategy
- 23.3.2.7.2. Product Strategy
- 23.3.2.7.3. Channel Strategy
- 23.3.3. Ocular Therapeutix, Inc.
- 23.3.3.1. Overview
- 23.3.3.2. Product Portfolio
- 23.3.3.3. Analyst Commentary
- 23.3.3.4. Key Financials
- 23.3.3.5. Recent Developments
- 23.3.3.6. Sales Footprint
- 23.3.3.7. Strategy Overview
- 23.3.3.7.1. Marketing Strategy
- 23.3.3.7.2. Product Strategy
- 23.3.3.7.3. Channel Strategy
- 23.3.4. Alimera Sciences
- 23.3.4.1. Overview
- 23.3.4.2. Product Portfolio
- 23.3.4.3. Analyst Commentary
- 23.3.4.4. Key Financials
- 23.3.4.5. Recent Developments
- 23.3.4.6. Sales Footprint
- 23.3.4.7. Strategy Overview
- 23.3.4.7.1. Marketing Strategy
- 23.3.4.7.2. Product Strategy
- 23.3.4.7.3. Channel Strategy
- 23.3.5. pSivida
- 23.3.5.1. Overview
- 23.3.5.2. Product Portfolio
- 23.3.5.3. Analyst Commentary
- 23.3.5.4. Key Financials
- 23.3.5.5. Recent Developments
- 23.3.5.6. Sales Footprint
- 23.3.5.7. Strategy Overview
- 23.3.5.7.1. Marketing Strategy
- 23.3.5.7.2. Product Strategy
- 23.3.5.7.3. Channel Strategy
- 23.3.6. Santen Pharmaceutical Co., Ltd
- 23.3.6.1. Overview
- 23.3.6.2. Product Portfolio
- 23.3.6.3. Analyst Commentary
- 23.3.6.4. Key Financials
- 23.3.6.5. Recent Developments
- 23.3.6.6. Sales Footprint
- 23.3.6.7. Strategy Overview
- 23.3.6.7.1. Marketing Strategy
- 23.3.6.7.2. Product Strategy
- 23.3.6.7.3. Channel Strategy
- 23.3.7. Taiwan Liposome Company Ltd.
- 23.3.7.1. Overview
- 23.3.7.2. Product Portfolio
- 23.3.7.3. Analyst Commentary
- 23.3.7.4. Key Financials
- 23.3.7.5. Recent Developments
- 23.3.7.6. Sales Footprint
- 23.3.7.7. Strategy Overview
- 23.3.7.7.1. Marketing Strategy
- 23.3.7.7.2. Product Strategy
- 23.3.7.7.3. Channel Strategy
- 23.3.8. Envisia Therapeutics
- 23.3.8.1. Overview
- 23.3.8.2. Product Portfolio
- 23.3.8.3. Analyst Commentary
- 23.3.8.4. Key Financials
- 23.3.8.5. Recent Developments
- 23.3.8.6. Sales Footprint
- 23.3.8.7. Strategy Overview
- 23.3.8.7.1. Marketing Strategy
- 23.3.8.7.2. Product Strategy
- 23.3.8.7.3. Channel Strategy
- 23.3.9. Eyegate Pharma
- 23.3.9.1. Overview
- 23.3.9.2. Product Portfolio
- 23.3.9.3. Analyst Commentary
- 23.3.9.4. Key Financials
- 23.3.9.5. Recent Developments
- 23.3.9.6. Sales Footprint
- 23.3.9.7. Strategy Overview
- 23.3.9.7.1. Marketing Strategy
- 23.3.9.7.2. Product Strategy
- 23.3.9.7.3. Channel Strategy
- 23.3.10. Valeant Pharmaceuticals International, Inc
- 23.3.10.1. Overview
- 23.3.10.2. Product Portfolio
- 23.3.10.3. Analyst Commentary
- 23.3.10.4. Key Financials
- 23.3.10.5. Recent Developments
- 23.3.10.6. Sales Footprint
- 23.3.10.7. Strategy Overview
- 23.3.10.7.1. Marketing Strategy
- 23.3.10.7.2. Product Strategy
- 23.3.10.7.3. Channel Strategy
- 23.3.11. Vision Ophthalmology Group GmbH
- 23.3.11.1. Overview
- 23.3.11.2. Product Portfolio
- 23.3.11.3. Analyst Commentary
- 23.3.11.4. Key Financials
- 23.3.11.5. Recent Developments
- 23.3.11.6. Sales Footprint
- 23.3.11.7. Strategy Overview
- 23.3.11.7.1. Marketing Strategy
- 23.3.11.7.2. Product Strategy
- 23.3.11.7.3. Channel Strategy
- 23.3.12. Clearside Biomedical
- 23.3.12.1. Overview
- 23.3.12.2. Product Portfolio
- 23.3.12.3. Analyst Commentary
- 23.3.12.4. Key Financials
- 23.3.12.5. Recent Developments
- 23.3.12.6. Sales Footprint
- 23.3.12.7. Strategy Overview
- 23.3.12.7.1. Marketing Strategy
- 23.3.12.7.2. Product Strategy
- 23.3.12.7.3. Channel Strategy
- 23.3.13. URSAPHARM Arzneimittel GmbH
- 23.3.13.1. Overview
- 23.3.13.2. Product Portfolio
- 23.3.13.3. Analyst Commentary
- 23.3.13.4. Key Financials
- 23.3.13.5. Recent Developments
- 23.3.13.6. Sales Footprint
- 23.3.13.7. Strategy Overview
- 23.3.13.7.1. Marketing Strategy
- 23.3.13.7.2. Product Strategy
- 23.3.13.7.3. Channel Strategy
- 24. Assumptions and Acronyms Used
- 25. Research Methodology
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook